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Background: The histo-blood group antigens are carbohydrate structures present in tissues and body ﬂuids,
which contribute to the deﬁnition of the individual immunophenotype. One of these, the Sda antigen,
is expressed on the surface of erythrocytes and in secretions of the vast majority of the Caucasians and
other ethnic groups.
Scope of review:We describe the multiple and unsuspected aspects of the biology of the Sda antigen and its
biosynthetic enzyme β1,4-N-acetylgalactosaminyltransferase 2 (B4GALNT2) in various physiological and
pathological settings.
Major conclusions: The immunodominant sugar of the Sda antigen is a β1,4-linked N-acetylgalactosamine
(GalNAc). Its cognate glycosyltransferase B4GALNT2 displays a restricted pattern of tissue expression, is
regulated by unknown mechanisms - including promoter methylation, and encodes at least two different
proteins, one of which with an unconventionally long cytoplasmic portion. In different settings, the Sda
antigen plays multiple and unsuspected roles. 1) In colon cancer, its dramatic down-regulation plays a
potential role in the overexpression of sialyl Lewis antigens, increasing metastasis formation. 2) It is
involved in the lytic function of murine cytotoxic T lymphocytes. 3) It prevents the development of muscu-
lar dystrophy in various dystrophic murine models, when overexpressed in muscular ﬁbers. 4) It regulates
the circulating half-life of the vonWillebrand factor (vWf), determining the onset of a bleeding disorder in a
murine model.
General signiﬁcance: The expression of the Sda antigen has a wide impact on the physiology and the
pathology of different biological systems.© 2013 Elsevier B.V. All rights reserved.1. Introduction
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ights reserved.as glycoproteins and glycolipids. A large proportion of the proteins
dissolved in blood, body ﬂuids and mucus are glycoproteins as well.
The structure of the sugar chains of glycoproteins and glycolipids
undergoes profound changes in a variety of pathological processes,
including cancer [1], inﬂammatory diseases and aging [2].
Most of the blood group antigens described are carbohydrates.
Formerly detected on the surface of erythrocytes, they were found
to be widely distributed in other tissues [3] and consequently were
named “histo-blood group” antigens in 1989 [4]. The most prominent
features of histo-blood group antigens are: i) their polymorphic expres-
sion, in that only a percentage of the population is genetically deter-
mined to express a given antigen; ii) the existence of “natural”
antibodies, in that individuals not expressing a given antigen frequently
(but not necessarily) develop antibodies against that antigen even in
the absence of previous immunization; iii) an individual (referred to
as “non-secretor”) may express a given antigen on the erythrocytes
and not in the secretions or vice versa [5].
The most important blood group system is the well-known ABO
system. However, a variety of “minor” blood group systems, including
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and tissue cells. The histo-blood group Sda, qualiﬁed as “public” due to
its high incidence, is one of these “non ABO” histo-blood group antigens.
Since its discovery in 1967, its importance in a variety of physiological
and pathological conditions has been increasingly recognized.2. Structure, distribution and biosynthesis of the Sda/Cad antigen
2.1. Structure and distribution
In 1967, two groups independently reported the presence of a carbo-
hydrate antigen, called Sda, on the erythrocytes and in secretions of the
vast majority of individuals of Caucasian origin [6,7]. The Sda was found
to be inherited as a dominant character suggesting the occurrence of a
new blood group antigen. In 1970, a comprehensive study was pub-
lished on the distribution of the Sda antigen in human and animal
body tissues and ﬂuids, using the inhibition of the agglutination of
Sda+ erythrocytes by anti-Sda antibodies as a measure of Sda activity
[8]. According to this study, summarized in Table 1, human saliva,
milk, meconium and urine can express the Sda antigenwith the highest
concentration being detected in urine. More than half of the people
whose red cells group as Sda−, still secrete Sda substance in the urine
or saliva [8,9], indicating that a different regulation of the biosynthesis
of this antigen occurs in kidney, salivary glands and bone marrow. The
percentage of individualswith an Sda negative phenotype in both eryth-
rocytes and urine was 4%, while anti-Sda antibodies were present in
about 50% of Sda− non-secretors. Among animals, the Sda antigen was
detected in a variety of mammals, with the highest Sda activity detected
in urine and kidney of guinea-pig, whereas no activity was detected in
the ﬁve bird species tested [8]. In considering these data, it should be
kept in mind that sometimes the number of individuals analyzed was
very small. Consequently, a percentage of 100% Sda+ individuals deter-
mined in a group of 10 or less does not have the same accuracy as the
percentage calculated on hundreds of individuals.Table 1
Sda activity in human secretionsa.
Secretion No. of individuals % individuals with Sda
activity in the secretionb
Urine
General population (above 5 years) 361 96
Individuals with Sda+ erythrocytes 22 100
Individuals with Sda− erythrocytes 13 75
Individuals with Sda− erythrocytes
and anti Sda in serum
9 0
Newborns 16 100
Children (1–9 years) 20 100
Pregnant women 16 100
Post partum 14 100
Milk 4 25
Feces
Newborns 4 100
Children (3–12) 4 75
Adults (19–84years) 12 8
Saliva
Individuals with Sda+ erythrocytes 66 94
Individuals with Sda- erythrocytes 14 43
Newborns 12 100
Data have been deduced from Ref [8].
a The test used was based on the ability of the sera of some individuals to induce the
erythrocyte agglutination of other ABO-compatible individuals. In the standard test, the
erythrocytes of a single reference individual, considered to be Sda+, were incubated
with the serum from another reference individual of Sda− phenotype and possessing
anti-Sda antibodies, resulting in erythrocyte agglutination. The addition to this reaction
of secretions from other individuals can inhibit agglutination, depending on the presence
in the secretion of molecules carrying the Sda epitope.
b The percentage of Sda+ individuals determined among small groups is not statistically
precise, owing to the small sample size and cannot be compared with the percentage
calculated on larger samples.Several lines of evidence indicated that the well-known urinary
Tamm–Horsfall glycoprotein (THGP) is a major carrier of the Sda anti-
gen in urine. In fact, the Sda activity of THGP fromdifferent donors strict-
ly correlated with their Sda red blood cell phenotype [10], while THGP
from Sda+ individuals was precipitated with anti-Sda sera [11]. In kid-
ney, the Sda antigen and THGP showed the same tissue distribution
in the distal convoluted tubules and collecting ducts [12]. However,
at least one other protein carrier of the Sda antigen with mucin-like
properties, different from THGP, is present in urine [13].
The structure of the Sda antigen was elucidated in the eighties. First,
a close relationshipwas established between theN-acetylgalactosamine
(GalNAc) content and Sda activity of THGP [10]; second, it was es-
tablished that the immunodominant GalNAc residue was β1,4-linked
to a galactose (Gal) residue [14]; third, a pentasaccharide with the
ability to inhibit anti-Sda-induced agglutination of Sda+ erythrocytes
was isolated by endoglycosidase treatment from the N-linked chains
of THGP and found to possess the following structure [15]:
GalNAcβ1;4 Neu5Acα2;3ð ÞGalβ1;4GlcNAcβ1;3Gal:
The Cad antigen was ﬁrst described in 1968 as a dominant character
in threemembers of aMauritian family [16]. Agglutination of Cad eryth-
rocytes by GalNAc-speciﬁc lectins (Dolichos biﬂorus, Helix pomatia)
(Table 2) led to the conclusion that the immunodominant sugar of the
Cad antigenwas GalNAc [17]. The observation that Cad samples reacted
strongly with anti-Sda antibodies [18] led to the conclusion that Cad
was a very reactive form of Sda, and was called super Sid or Sda++.
Membrane glycoproteins of the erythrocytes of Cad individuals
displayed reduced electrophoretic mobility [19]. The major Cad struc-
ture associated with glycophorin A was a type 3 O-linked carbohydrate
chain with the following structure [19–21]:
GalNAcβ1;4 Neu5Acα2;3ð ÞGalβ1;3 Neu5Acα2;6ð ÞGalNAc‐Ser=Thr
and was a powerful inhibitor of the anti-Sda agglutination of Sda+
erythrocytes. Interestingly, a comparative study of glycophorin A from
Cad, Sda+ and Sda− individuals revealed the absence of the above-
reported Cad-active O-linked pentasaccharide in glycophorin A from
both Sda+ and Sda− individuals [22]. In addition, in erythrocytes from
Cad individuals, the glycolipid sialylparagloboside was largely modiﬁed
with a β1,4-linked GalNAc, giving rise to the structure [23]:
GalNAcβ1;4 Neu5Acα2;3ð ÞGalβ1;4GlcNAcβ1;3Galβ1;4Glc‐ceramide:
The percentage of sialylparagloboside molecules elongated by the
GalNAc residues was about 70% in erythrocytes from Cad individuals
and less than 20% in those from Sda+ individuals [24]. Thus, the three
Sda/Cad-active structures reported above share the following minimal
structure:
GalNAcβ1;4 Neu5Acα2;3ð ÞGalβ‐R:
This trisaccharide is also found in the GM2 ganglioside:
GalNAcβ1;4 Neu5Acα2;3ð ÞGalβ1;4Glc‐ceramide:
However, an enzyme preparation from human kidney catalyzed the
transfer of radiolabeled GalNAc to sialylparagloboside but not to gangli-
oside GM3 (the GM2 precursor), indicating that the GalNAc-transferase
responsible for the biosynthesis of Sda/Cad antigens was not able to
convert GM3 into GM2 [24].
In conclusion, Cad and Sda blood group antigens appear to
share the antigenic determinant, which can be expressed by N- or
O-linked chains of glycoproteins and by long sugar chain ganglio-
sides (sialylparagloboside), but not by short sugar chain gangliosides
(GM3). Sda and Cad antigens are likely the product of the same bio-
synthetic enzyme. The difference between the two phenotypes may
Table 2
Binding speciﬁcity of the most widely used tools for the detection of the Sda/Cad antigen.
Antibody or lectin Speciﬁcity References
Dolichos biﬂorus lectin (DBA) α-GalNAc [16]
Cad antigen
Helix pomatia lectin (HPA) α-GalNAc [24]
Cad antigen
Vicia villosa B4 lectin (VVA) α-GalNAc [17]
Cad antigen
CT1 antibody Siaα2,3(GalNAcβ1,4)Gal-R [43]
GM2 containing Neu5Ac [93,94]
CT2 antibody Siaα2,3(GalNAcβ1,4)Gal-R [43]
Sda antigen containing Neu5Gc [93,94]
KM 531 antibody Sda/CadNGM2 [67]
KM694 antibody Sda/CadNGM2 [68]
Antibodies CT1 and CT2 have both been reported to react with human THGP [43] whose
sialic acid is Neu5Ac, because Neu5Gc is not synthesized by human tissues. However, in
another study Neu5Gc was found to be mandatory for reactivity with CT2 [94]. This dis-
crepancy can be explained by the different tests used.
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ity of the biosynthetic enzyme in Cad individuals leading to the addi-
tion of the β1,4-linked GalNAc on a higher percentage of carrier
molecules. Moreover, some acceptor molecules, which could be poor
acceptors for the enzyme of Sda+ individuals, could be efﬁciently glyco-
sylated by the enzyme of Cad individuals, leading to structures not
detectable in Sda+ individuals, such as the O-linked structure derived
from glycophorin A reported above. Thus, the difference between Cad
and Sda appears to be both quantitative and qualitative.
2.2. Identiﬁcation of the Sda synthase: β-1,4-N-acetylgalactosaminyl-
transferase 2 (B4GALNT2)
The very high Sda activity in kidney and urine of guinea-pigs
[12] prompted F. Seraﬁni-Cessi to investigate the presence of
the Sda biosynthetic enzyme in guinea-pig kidney. This approach
led to the identiﬁcation of a GalNAc-transferase, now known as β-
1,4-N-acetylgalactosaminyltransferase 2 [ofﬁcial symbol of the
human gene, according to HUGO (http://www.genenames.org/):
B4GALNT2. Previously used names: UDP-GalNAc:Neu5Acα2–3Galβ-R
β1,4-N-acetylgalactosaminyltransferase 2; β1,4GalNAcT-II; GALGT2].
This glycosyltransferase catalyzes the transfer of GalNAc from UDP-
GalNAc to the N-linked chains of THGP and fetuin and not to their
asialylated counterparts. This ﬁnding suggested that in the sequential
synthesis of the Sda antigen the addition of β1,4-linked GalNAc
occurred after the addition of α2,3-linked sialic acid [25]. Despite the
fact that only THGP from Sda− individuals lacked GalNAc residues,
both THGP from Sda+ and Sda− individuals were good acceptors of this
GalNAc-transferase activity in vitro [25], suggesting that several free
potential acceptor sites of GalNAc-transferase exist in the THGP of Sda+
individuals. It was subsequently reported that the guinea-pig enzyme
could catalyze the transfer of a GalNAc residue to a free α2,3-sialylated
oligosaccharide, and not to its α2,6-sialylated isomer or to the GM3
ganglioside [26]. In addition, this GalNAc residue could be released
only by β-hexosaminidase and not by α-hexosaminidase treatment,
provided that the sialyl residue was preliminarily removed by chem-
ical hydrolysis [26]. Altogether, these data indicated that the guinea-
pig enzyme had properties consistent with those of an Sda synthase.
Strikingly, the enzyme could not be extracted by conventional incuba-
tion with a non-ionic detergent, such as Triton X-100, and also required
KCl [27]. The partially puriﬁed enzyme showed activity also towards O-
linked derived structures, such as Neu5Acα2,3Galβ1,3GalNAcol. Inter-
estingly, the enzyme was also highly expressed in colon and kidney
medulla [28].
The properties of the human kidney enzyme were very similar, but
not identical, to those of the guinea-pig enzyme, in that only the latter
was able to transfer GalNAc to glycophorin [29]. Moreover, the humanenzyme was able to act on a long sugar chain ganglioside, such as
sialylparagloboside, although not on GM3 [24,29]. A β1,4GalNAc-
transferase activity with similar, if not identical, enzymatic properties
was identiﬁed in human plasma [30], urine [31] and large intestine,
in which it shows a proximal to distal gradient of expression [32].
Although microarray analysis has suggested that a transcript similar to
B4GALNT2 may be expressed in intestinal cells of developing zebraﬁsh
[33], no information on this enzyme activity in lower vertebrates is
available.2.3. The Sda antigen and B4galnt2 in mouse lymphocytes: the CT antibodies
It has been known since the seventies that populations of mouse
cytotoxic T (CT) lymphocytes expressed on speciﬁc glycoproteins a car-
bohydrate antigen which could be recognized by the GalNAc-speciﬁc
lectin from Vicia villosa (Table 2) [34,35]. This antigen allowed CTL to
be discriminated and isolated from other lymphocyte populations,
including those with cytotoxic activity but not belonging to the T cell
lineage (such as NK cells). In 1984, it was reported that the VV6 clone
of the murine CTL cell line B6.1.SF.1 resistant to V. villosa lectin lacked
β1,4-linked GalNAc residues at the non-reducing ends of conventional
O-linked structures [36]. Enzymatic studies showed that the VV6 clone
lacked GalNAc-transferase activity [37] which, in wild type cells,
displayed very similar properties to those of the GalNAc-transferase
described one year earlier in guinea-pig kidney [25]. Among murine T
cell populations, the level of GalNAc-transferase activity was generally
higher in those with cytotoxic function [38]. Themonoclonal antibodies
CT1 and CT2 (Table 2) were obtained from a screen for antibodies
reacting with amurine CTL clone andwere found to recognize carbohy-
drate antigens on CTL [39] and to block speciﬁc target cell lysis [40]. The
causal relationship between lytic activity and CT antigen expressionwas
conﬁrmed by the ﬁnding that the induction of lytic ability by IL-2 in a
mouse hybridoma cell line paralleled the expression of CT antigens
[41]. Subsequent analysis showed that CT1 and CT2 antibodies recog-
nized similar, but not identical, sialic acid-containing epitopes [42].
Both antibodies bound to Tamm–Horsfall glycoprotein of Sda+ but not
Sda− individuals in a solid phase assay and to erythrocytes of Cad indi-
viduals [43]. Among lymphocytes associated with mouse small intes-
tine, the expression of the CT antigens was associated with those
expressing the Lyt-2 antigen (CD8), not only with those with constitu-
tive cytotoxic activity [44]. Interestingly, in the small intestine the CT1
antibody stained the epithelial cells of the lower crypt (which contain
the intestinal stem cells), while CT2 stained the entire villi [44]. During
mouse embryonic development, the CT1 antigen was expressed by
a relevant percentage of thymocytes, namely a subset of immature
double negative (CD4−/CD8−) thymocytes [45]. During thymocyte
differentiation in adult mice, the CT1 antigen was expressed only by
early T-lineage-committed cells: the signal leading to down-regulation
of B4GALNT2 and consequently to switch-off of the CT1 antigen appears
to be mediated through the pre-TCR complex [46]. Priming murine
CTL precursors with different antigens gave rise to polarized CTL
populations: one produced a cytokine spectrum similar to that of T
helper 1 cells involved in anti-microbial immunity (IFN-γ and TNF-α,
but not IL-4, IL-5, and IL-10), while the second produced a cytokine
spectrum (IL-4, IL-5, IL-10 but little or no IFN-γ and TNF-α) similar to
that of T helper 2 cells involved in anti-parasite defence. Interestingly,
only CTL of the ﬁrst type were found to react with CT1 [47], suggesting
that this antigen distinguishes functionally different CTL populations.
In human peripheral blood lymphocytes, CT1 and CT2 antibodies
marked only a small percentage of double positive CD4+ CD8+ cells.
This percentagewas higher in patientswith systemic lupus erythemato-
sus but not in those with other autoimmune diseases [48]. Stimulation
with phytohaemagglutinin (PHA) or anti-CD3 antibodies increased the
percentage of CD4+ and CD8+ lymphocytes reactive with CT1 or CT2
antibodies [48]. The latter data suggest that in humans, the expression
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affected by lymphocyte stimulation.
2.4. Molecular cloning of B4GALNT2
Taking advantage of the availability of the Sda-reactive CT1 and
CT2 antibodies, the ﬁrst mouse B4galnt2 cDNA was successfully
cloned in 1994 using a mammalian transient expression cloning
approach [49]. The cloned cDNA predicted a 510 amino acid trans-
membrane protein with a type 2 topology, characteristic of other
Golgi-glycosyltransferases, with a single potential N-glycosylation site.
In a murine CTL cell line, a single 4.4 kb transcript was detected by
Northern blot analysis. Like the previously characterized B4GALNT2
from various origins, the cloned recombinant enzyme displayed an
absolute requirement for an α2,3-linked sialic acid in the acceptor. The
ﬁrst partial human B4GALNT2 cDNA was reported two years later [50],
while the ﬁrst human full-length clones were independently obtained
from the human colon cancer cell line Caco-2 by two groups in 2003
[51,52]. The human B4GALNT2 gene maps on 17q21.33 and encom-
passes 11 coding exons. Northern blot [52] and PCR analyses [51] indi-
cated the existence of multiple transcripts diverging in their 5′- and
3′-UTR, some of which were very long (about 9000bp), and the occur-
rence of at least two alternative ﬁrst exons (Fig. 1). Five B4GALNT2
transcripts were mainly expressed in colon and to a lower extent in
ileum, stomach and kidney [52]. The long exon 1 (exon 1L) is 253 nt
long, while the short exon 1 (exon 1S) is 38 nt long, leading to two tran-
script variants differing at their 5′end (GenBank accession number
NM_153446 andNM_001159387). Both exon 1L and 1S contain a trans-
lational start site. Consequently, the human B4GALNT2 gene can give rise
to at least two different transmembrane peptides, divergent in their
amino-terminal portion (Fig. 1): a 566 aa long form with a very long
cytoplasmic tail and a 506 aa short form. Recombinant expression of
either protein isoform in the colon cancer cell line LS174T revealed
that the shorter form was associated with higher enzyme activity than
the long form [53]. Beside these two experimentally detected transcript
forms, GenBank predicts a third transcript variant (GenBank accessionATG
ATG
1L
ATG1M
1S
0.26 0.16 7.5 0.6 10.6 3.7 2.4
253 201 138 107 38 1851 38
E1M E1S E1L E2 E3 E4 E5 E6
Short form
Long form
Soluble form
(theoretical)
TM
TM
ATG
E2 E3 E4 E
Fig. 1.Organization of the human B4GALNT2 gene and its transcripts. The gene is comprised of 1
is reported above the exons. Numbers below the introns indicate the approximate intron lengt
the coding portion only. The short and long transcript forms are originated by the alternative
transmembrane proteins diverging in their amino-terminal portion. The predicted transme
but has never been conﬁrmed experimentally so far. It is originated by exon 1M which lacks
are inside exon 2, around the end of the transmembrane encoding sequence. Consequently, thnumber NM_001159388) with a third, 51 nt long, ﬁrst exon (called 1
Middle, 1M in Fig. 1) which has never been experimentally reported.
Exon 1M lacks any ATG translational start codon, while two in frame
ATG potential translational start codons are located in exon 2, around
the end of the transmembrane domain. Consequently, the predicted
peptide would lack the transmembrane region, generating a putatively
soluble form of the enzyme (Fig. 1). It has been generally thought that
the enzymatically active soluble forms of B4GALNT2 described in plasma
[30], urine [31] and conditioned medium of differentiated Caco-2 cells
[54] derive from the proteolytic cleavage of the membrane-bound
form(s), as occurs for other glycosyltransferases, including the well-
known sialyltransferase ST6GAL1 [55]. However, the experimental
detection of a transcript containing exon 1M would support the
existence of another mechanism, based on alternative ﬁrst exon
use and/or different promoter usage.
The long protein isoform of B4GALNT2 is characterized by the
unusual length of its cytoplasmic tail (67 aa), which is one of the longest
among glycosyltransferases and further suggests its involvement in a
very speciﬁc function. This is reminiscent of B4GALT1, another trans-
Golgi glycosyltransferase, which also exists in short and long forms
diverging in their N-terminal portion. Both B4GALT1 protein isoforms
are Golgi-resident enzymes, while the long protein isoform may also
be localized to the cell membrane, acting as a receptor for extracellular
matrix components [56,57]. B4GALT1 provides an interesting example
of a mechanism used by mammals to recruit a gene which serves a
dual role: N-glycan biosynthesis in most tissues and lactose synthesis
speciﬁcally in lactating mammary glands [58,59].
A soluble recombinant enzyme displayed good activity towards
α2,3-sialylated type 1 (Galβ1,3GlcNAc), type 2 (Galβ1,4GlcNAc) and
core 1 O-linked (Galβ1,3GalNAc) acceptors [52]. The structure of the
carbohydrate chains shown to be carriers of the Sda/Cad antigen or to
be acceptors for the B4GALNT2 enzymatic activity is displayed in
Fig. 2. B4GALNT1 (GM2 synthase) catalyzes the addition of GalNAc in
β1,4-linkage to the Gal residue of ganglioside GM3, giving rise to GM2
[60]. This reaction is similar to that catalyzed by B4GALNT2, except for
the presence of α2,3-linked sialic acid in the acceptor, which is notTAA
TAA
TAA
1.3 3.4 1.8 2.4 0.6
1 87 188 141 220 202
E7 E8 E9 E10 E11
Approximate intron 
length (kb)
Exon length 
5 E6 E7 E8 E9 E10 E11
1 exonswith at least three alternative ﬁrst exons: exons 1S, 1L and 1M. Exon length (in bp)
h expressed in kb. The coding regions are depicted in gray. The length of exon 11 refers to
presence of exon 1S or 1L. Both contain a translational start codon and give rise to two
mbrane domain is depicted in dark gray. The “soluble form” is predicted by GenBank,
a translational start codon. Two potential ATG starting codons of this putative transcript
e protein encoded by this transcript should be a soluble form of B4GALNT2.
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proximity to the reaction site, which is incompatible with the activity of
B4GALNT2. A comparison of the predicted amino acid sequences of
B4GALNT1 and B4GALNT2 reveals extensive homology in the C-
terminal region encompassing the catalytic domain, suggesting a com-
mon phylogenetic origin of the two genes.
3. The Sda antigen in physio-pathological conditions
3.1. Onco-developmental regulation
The dependence of B4GALNT2 on the mechanisms regulating
ontogenic development and cell differentiation was formerly suggested
by the observation that the guinea-pig kidney enzyme showed aﬁvefold
increase after birth [28]. A developmental regulation of B4GALNT2 was
also observed in rat colon, in which the enzyme was practically absent
at birth, increased slowly in the ﬁrst days of life and then rapidly after
weaning [63]. Consistently, the Sda antigen was not detected in human
fetal colonic mucins [64]. However, as mentioned in Table 1, the feces,
urine and saliva of human newborns have been reported to express
high Sda activity [8]. The origin of this discrepancy remains to be
established.
A higher B4GALNT2 activity has been observed in the poorly differ-
entiated cells of the colonic crypt [63], in agreement with the observa-
tion that CT1 antibody selectively stained the cells at the basis of the
intestinal crypt [44]. Conversely, Caco-2 cells, one of the few in vitro
models of intestinal differentiation, showed an increased B4GALNT2
expression concomitantly with a differentiated phenotype [65].
In human colonic cancer, B4GALNT2 activity exhibits a dramatic
down-regulation, compared with the normal surrounding mucosa
[32,53], due to down-regulated expression of the mRNA [50]. Interest-
ingly, a small percentage of individuals expressing little or no activity
in normal colon was found by both European [32,53] and Japanese
[50] studies, suggesting that these individuals were probably Sda−. Sda
antigen expressionwas reduced in colon cancer, comparedwith normal
mucosa paralleling that of the enzyme expression [66].
Using the monoclonal antibody KM531 (Table 2), speciﬁc for both
GM2 and Sda antigen, GM2 was not expressed by samples of normal gas-
tric mucosa or of peptic ulcer but was expressed by gastric carcinoma
specimens [67]. However, in the same samples of normal gastricmucosa
KM531 detected other glycolipids with a lower TLC mobility, mostlyFig. 2. Structure of the major oligosaccharide chains carrying the Sda/Cad antigen. The term
type 2 lactosaminic chains, (both present in the distal regions of N- and O-linked chains), core 1
(indicated as R1-R5 structures), can undergo α2,3-sialylation. The subsequent addition of a β1sialylparagloboside with a β1,4-linked GalNAc residue (see above).
These long sugar chain gangliosideswere not detected in the fewgastric
cancer specimens examined [67]. Owing to the known ability of
B4GALNT2 to glycosylate sialylparagloboside [24] and not GM3, it was
likely that in gastric cancer B4GALNT2 was down-regulated while
B4GALNT1 (GM2 synthase) was up-regulated. Indeed, the B4GALNT2
gene was found to be expressed in gastric mucosa and down-
regulated in gastric cancer because of a down-regulation of its mRNA
[50]. Later on, the same group [68] showed that in normal human stom-
ach, B4GALNT2 activity and Sda active glycolipids (detectedwith anoth-
er anti Sda-speciﬁcmonoclonal antibody: KM 694)were both present in
a cell fraction enriched with chief cells (the stomach cells releasing
pepsinogen).
Sialyl Lewis x (sLex) and sialyl Lewis a (sLea) antigens are well-
known fucosylated carbohydrate structures (Fig. 3A) which act as li-
gands for the cell adhesion molecules of the selectin family and play a
fundamental role in leukocyte extravasation. The frequent overexpres-
sion of these antigens in cancer cells contributes tometastasis formation
because it allows the interaction of the circulating cancer cells released
by the tumor with selectins expressed on endothelial cells. In colon
cancer, the overexpression of sLex/a is not due to the overexpression of
their cognate fucosyltransferases [69]. An intriguing possibility is that
the level of B4GALNT2 plays a role in regulating sLex/a expression
(Fig. 3). The structural similarity between the Sda and sLex/a antigens
suggests that their biosynthesis might be mutually exclusive. In fact,
both derive from the substitution of anα2,3-sialylatedGalβ1,3/4GlcNAc
chain: the ﬁrst with a GalNAc residue β1,4 linked to galactose, the
second with a fucose residue α1,3/4-linked to GlcNAc (Fig. 3A). In
vivo, it was shown that mucins from normal descending colon highly
expressed the Sda epitope and poorly expressed sLex-containing struc-
tures, whereas no carbohydrate chains carrying both the Sda and the
sLex determinantswere detected [70]. In vitro, two groups independent-
ly demonstrated that the forced expression of B4GALNT2 in cancer cell
lines of gastrointestinal origin resulted in a down-regulation of sialyl
Lewis antigens. One group expressed the long protein isoform of
B4GALNT2 in gastric cancer KATO III cells and in colon cancer HT29
cells, observing the loss of sLex expression in both cell lines and a strik-
ing reduction of their metastatic ability [68]. The other study showed
that both the long and the short protein isoforms of B4GALNT2 were
able to induce the expression of the Sda antigen and the inhibition of
sLex in LS174T cells [53]. In all these in vitro cellular models the Sda orinal galactose residue of different types of carbohydrate chains, including type 1 and
and core 3 O-linked chains, as well as long sugar chain glycolipids, such as paragloboside
,4-linked GalNAc, mediated by B4GALNT2, leads to formation of the Sda/Cad antigen.
AB
Fig. 3. Competition between the Sda and sLea/x antigens. A: The Sda and sLea/x antigens
derive from the substitution of a α2,3-sialylated type 1 or type 2 chain. The addition
of β1,4-linked GalNAc to Gal leads to the expression of the Sda antigen, while that of
α1,4/3-linked fucose to GlcNAc leads to the expression of sLea/x antigens. The expression
of the two types of antigen ismutually exclusive because the Sda antigen is not a substrate
ofα1,4/3-fucosyltransferases and vice versa. B: In colon cancer, themarked increase in sLex
expression is not supported by increased fucosyltransferase expression (arrows of
the same width), while the reduced B4GALNT2 activity present in cancer tissues
(narrow arrow) is likely responsible for the shift of the Sda/sLex equilibrium towards sLex.
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cules. A model in which the regulation of sLex expression in colonic
tissues is controlled by the level of competing B4GALNT2 is depicted
in Fig. 3B.
3.2. Expression in intestinal infections
In rat small intestine, infection with the parasite Nippostrongylus
brasiliensis causes different alterations of mucin glycosylation, including
a decrease of the Neu5Gc/Neu5Ac ratio and the appearance of O-linked
oligosaccharides terminating with the Sda epitope [71]. The maximum
expression of Sda carrying structures increased from day 8 postinfection
to peak at the time of parasite expulsion. This change could be due to
activation of B4GALNT2 in small intestine of infected rats, but no
evidence of such activation has been provided so far. In mice small
intestine, parasite infection induced the synthesis of an O-linked oligo-
saccharide with a putative terminal GalNAc but devoid of sialic acid.
Owing to the known strict speciﬁcity of B4GALNT2 for sialylated accep-
tors, its involvement in the biosynthesis of such a structure can be ruled
out [72].
The gutmicrobiota comprises trillions ofmicrobes living in the intes-
tine and forming a complex ecological community that inﬂuences nor-
mal physiology and susceptibility to disease. A recent study showed
that B4galnt2 KO mice displayed signiﬁcant alterations of the gut
microbiota compared with normal mice [73]. This ﬁnding suggests
that B4galnt2 exerts a role at the interface between commensal
microbiota and host immune system. However, unlike other glycosyl-
transferases such as fucosyltransferase 2, whose expression requires
bacterial colonization of the gut, B4galnt2 also seems to be expressed
in germ-free mice [73].
4. Epigenetic regulation of B4GALNT2
Exons 1L, 1S and 1M of the human B4GALNT2 gene are embedded in
genomic sequences with the features of a CpG island, suggesting that
DNAmethylation could play a role in regulating B4GALNT2 gene expres-
sion, in particular in the down-regulation observed in gastrointestinalcancers. This point was formerly investigated in a paper showing that
the twopreviously described transcripts driving the expression of either
the long or short protein isoforms of B4GALNT2 were detectable by RT-
PCR (but only after 40 ampliﬁcation cycles) in some gastrointestinal
cell lines and not in others [74]. In the cell lines not expressing the
B4GALNT2 transcripts, the promoter region was found to bemethylated
and B4GALNT2 gene expression was restored by treatment with the
DNAmethylation inhibitor 5′aza 2′-deoxycytidine [74]. However, a pre-
viously reported semiquantitative RT-PCR analysis with amore conven-
tional number of ampliﬁcation cycles (30–35) in a panel of colon cancer
cell lines and a normal mucosa specimen revealed a clearly detectable
transcript level only in differentiated Caco-2 and normal mucosa [51].
This ﬁnding is in agreement with enzyme activity data showing that
B4GALNT2 activity is practically undetectable in colon cancer cell
lines, with the exception of Caco-2 after differentiation [65]. However,
even in differentiated Caco-2, the level of enzyme activity is approxi-
mately about 10% that of normal colonic mucosa. The methylation
level of several glyco-genes, including B4GALNT2, was investigated in
human gastrointestinal cancers and cell lines [75]. The B4GALNT2 gene
was found to be methylated in about half of the gastric cancer cases
examined and in the majority of gastric and colon cancer cell lines.
Treatment of cell lines with anti DNA-methylation agents induced a
weak expression of the B4GALNT2 transcript and Sda antigen [75]. Alto-
gether, these results are consistent with the view that methylation of
the B4GALNT2 genomic regulatory region plays a role in switching off
gene expression during carcinogenesis of gastrointestinal tissues. This
is reﬂected by the very low level ofmRNA expression and enzyme activ-
ity in cell lines (including Caco-2), even lower than that expressed by
many colon cancer surgical specimens, suggesting that in vitro culture
further inhibits B4GALNT2 gene expression. Removal of epigenetic
marks leads to a level of enzyme activation which remains far-
removed from that of the normal colonic mucosa. This suggests that
other major mechanisms are involved in regulation of this gene in colo-
rectal tissues. In particular, the set of transcription factors necessary to
ensure the high levels of expression measured in normal human colon
may not be properly expressed in cancer cell lines and tumor tissues.
Thus, removal of the epigenetic blockswould have the effect of releasing
the brakes of a vehicle, rather than igniting the engine.
5. Multiple roles of the Sda antigen
Studies in animal model systems have revealed a role for the Sda
antigen in the regulation of physiological mechanisms, such as hemo-
stasis or reproduction, as well as unexpected effects on neuromuscular
diseases.
5.1. Hemostasis
Von Willebrand factor (vWf) is a plasma glycoprotein that plays an
essential role in hemostasis by stabilizing coagulation factor VIII and
mediating the adhesion and aggregation of platelets to sites of vascular
injury. vWf is produced exclusively by megakaryocytes and endothelial
cells. Von Willebrand disease comprises a heterogeneous group of
bleeding disorders caused by qualitative or quantitative abnormalities
of vWf. While a percentage of the cases with a quantitative reduction
of vWf is due to mutation of the vWf gene, other cases are likely due
to mutations of modiﬁer genes. The plasma level of vWF in RIIIS/J
mice is about twentyfold lower than that of normal C57BL6/J mice.
MvWf1 is a major modiﬁer locus determining vWF levels in RIIIS/J
mice. This locus encodes a gain of function regulatory mutation of the
B4galnt2 gene which determines a switch in the tissue expression pat-
tern from gastrointestinal/epithelial to vascular endothelium [76,77].
The genomic region responsible for the switch lies approximately
30 kb upstream of the B4galnt2 gene [78]. In comparison with C57BL6/
J mice, in RIIIS/J mice this sequence shows 2–3% single nucleotide
(SNP) divergence as well as large insertion and deletions, resulting in
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B4galnt2 results in expression of the Sda antigen on the sugar chains of
vWF and its consequent rapid clearance from the blood, accounting
for the reduced vWF levels. The fact that several inbred mouse strains,
including ﬁve strains derived from the wild, share this phenotype sug-
gests that the endothelial switch is due to positive selection through a
still unknown beneﬁt [79]. However, a recent study suggested that the
putative beneﬁt could result not from the gain of B4galnt2 in endothelia,
but rather from its loss in intestine [80]. It remains to be established
whether polymorphisms of the B4GALNT2 gene are responsible for
reduced vWF levels in humans.
5.2. Reproduction
The Sda antigen is expressed by porcine primordial germ cells and by
a subpopulation of spermatogonia in cattle, pigs, horses and lama [81],
and also by theN- andO-glycans ofmurine zona pellucida glycoproteins
[82], indicating that both male and female gametes can express this
antigen whose biological signiﬁcance remains to be elucidated.
Moreover, the major N-glycan of bovine pregnancy-associated gly-
coproteins, which are secretory proteins of trophoblast cells in rumi-
nants, is a large structure whose four antennas are terminated by the
Sda antigen [83].
In primary cultures of mouse endometrial cells, the B4galnt2mRNA is
up-regulated by progesterone and down-regulated by estrogens [84],
while in mouse uterine tissues the expression of B4galnt2 mRNA starts
at the peri-implantation stage (embryonic day 3.5) and peaks at embry-
onic day 10.5, in parallel with the level of placental progesterone pro-
duction. B4galnt2 expression decreases as estrogen increases during
pregnancy. In vivodown-regulation of B4galnt2 by siRNA treatment effec-
tively reduced the number of implanted embryos [84]. Transfection of a
mouse full-length B4galnt2-GFP chimera in the blastocyst trophectoderm
cells in blastocyst revealed a plasma membrane localization in both
cases [85]. By contrast, in uterine tissues of pregnant mice, the B4galnt2
protein appeared to be localized in cytoplasm (including organelles)
and not on the plasmamembrane. Attachment of the blastocyst to endo-
metrial cells in vitro can be inhibited by either antibodies against B4galnt2
or lectins recognizing the Sda epitope [85]. These data indicate that the
Sda antigen is likely involved in embryo attachment.
Glycodelin is a human glycoprotein existing in four isoforms:
glycodelin-A (GdA) from the amniotic ﬂuid; glycodelin-F (GdF) from fol-
licular ﬂuid; glycodelin-C (GdC) from cumulus matrix, and glycodelin-S
(GdS) from seminal plasma. The four molecules share the same peptide
and differ only for the N-linked chains. In particular, the major complex
type GdS glycans are bi-antennary structures very rich in fucosylated
structures, such as Lewis x and Lewis y antigens. A portion of the N-
linked chains of all three female glycodelins are decorated by the Sda an-
tigen [86]. However, while this is the only sialylated structure in GdC,
both GdF and GdA contain α2,6-sialylated glycans. Both GdF and GdA
display immunosuppressive activity which is lacking in GdS and GdC
and is likely due to α2,6-sialylated structures. The immunomodulatory
activity of GdA protects the fetus from the maternal immune response
through mechanisms including the induction of T-cell apoptosis,
skewing of T-cell differentiation toward the Th-2 phenotype and modu-
lation of the activities of other immune cells such as natural killer, B-, and
dendritic cells. In gestational diabetes mellitus, a decrease of the expres-
sion of high mannose chains and of theα2,6-sialylation of GdA N-linked
chains and an increase in the structures carrying the Sda antigen were
observed. These changes in GdA glycosylation were accompanied by a
reduction of GdA immunosuppressive activities [87].
5.3. Neuromuscular tissues
The presence of GalNAc-containing carbohydrates at the neuromus-
cular junction was formerly detected with GalNAc-speciﬁc lectins from
D. biﬂorus and V. villosa in a variety of vertebrates (human, mouse,rabbit, guinea pig, chick, frog, axolotl, snake, ﬁsh, lamprey), and found
to be associatedwith both the enzyme acetylcholine esterase and a gly-
colipid [88,89]. It was subsequently reported that these GalNAc residues
play a role in the clustering of acetylcholine receptors (AchR) induced
by a large proteoglycan, called agrin, during organization of the neuro-
muscular synapse [90]. In addition, GalNAc was found in both the
presynapticmotor neuron [91,92], where it is carried by the GM2 gangli-
oside and recognized by the CT1 antibody, and in the postsynaptic
structures, where it is carried by glycoproteins and long sugar chain
gangliosides and is recognized by the CT2 antibody [93]. The expression
of CT1 and CT2 antigens in the pre- and postsynaptic termini is depen-
dent on the expression of B4galnt1 and B4galnt2 respectively [93].
Moreover, the different reactivity of CT1 and CT2 antibodies is at least
in part explained by the preference of CT1 for Neu5Ac and of CT2 for
Neu5Gc [94]. In B4galnt2 KO mice, an intracellular accumulation of
AchRwithin endosomes of skeletal myoﬁbers was observed, suggesting
that the Sda antigen is necessary for proper AchR routing. Instead, intra-
cellular transport of AchR was normal in B4galnt1-KO mice [93].
The dystrophin-associated protein complex (DAPC) comprises sev-
eral proteins whose ultimate role is to connect the F-actin cytoskeleton
of the muscular ﬁbers with the laminin of the extracellular matrix. The
DAPC is formed by intracellular (dystrophin, dystrobrevins), transmem-
brane (β-dystroglycan) and extracellular (α-dystroglycan) proteins
[95]. Mutations of the genes encoding DAPC proteins destabilize this
complex, leading to loss of membrane integrity and ultimately to mus-
cular dystrophy. The best known of these conditions is Duchenne mus-
cular dystrophy (DMD), a devastating human X-linked disease caused
by the lack of dystrophin. A goodmurinemodel of DMD, not expressing
dystrophin, is the mdxmouse.
α-Dystroglycan carries a very speciﬁc type of O-glycosylation in
which a mannose residue is linked to serine or threonine and is further
elongated with GlcNAc, Gal and sialic acid monosaccharides, giving rise
to a structure analogous to the antennae of N-linked chains [96]. The
importance of this structure is demonstrated by the extremely severe
phenotypes of dystrophic syndromes, such asWalker–Warburg disease
and muscle–eye–brain disease, in which the addition of O-linked man-
nose or N-acetylglucosamine, respectively, is impaired [97,98] because
of the deﬁciency of the cognate glycosyltransferases. Owing to the
very restricted expression of B4galnt2 inside the neuromuscular junc-
tion, these α2,3-sialylated lactosaminic type O-mannose linked chains
ofα-dystroglycan are decorated by β1,4-linked GalNAc only at the neu-
romuscular junctions [88,91,99] in adult mice. Another molecule of the
neuromuscular junction which can be decorated by the Sda antigen
is agrin. This modiﬁcation increases agrin binding to myotubes and
enhances its AchR clustering activity [100].
When transgenic mice ectopically overexpressing B4galnt2 in skele-
tal muscle ﬁbers (outside the neuromuscular junction) were crossed
with mdx mice, the resulting phenotype displayed a near complete
reversion of dystrophy [101]. In addition, B4galnt2 expression in the
skeletal muscle induced reversion of the dystrophic phenotype in a
variety of other murine models of dystrophy, including DGS654A, in
which processing of the dystroglycan molecule is inhibited because of
a point mutation [102], MDC1A, in which α2-laminin is deﬁcient [103]
and mice lack α-sarcoglycan [104]. Ectopic expression of B4galnt2 also
showed protection in a model of muscle damage induced by response
to eccentric contraction [105].
To understand the mechanisms linking B4galnt2 expression and
reversion of the dystrophic phenotype, it should be remembered that
while several proteins of DAPC are localized both on themuscular ﬁbers
and at the neuromuscular junctions, others are present in either the
ﬁbers or the junctions. At least two differences betweenmuscular ﬁbers
and neuromuscular junctions, illustrated in Fig. 4, are of particular rele-
vance. First, in the neuromuscular junctions the role played by dystro-
phin in connecting F-actin ﬁlaments with cell membranes is also
played by utrophin, a dystrophin paralogue. Second, in the neuromus-
cular junctions (not in muscular ﬁbers) the binding of α-dystroglycan
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exists at the neuromuscular junction with structures and functions
similar and distinct from those present on muscle ﬁbers. When
B4galnt2 is extrasynaptically expressed in muscle ﬁbers, the α2,3-
sialylated lactosaminic O-mannose-linked glycans of α-dystroglycan
become modiﬁed by β1,4-linked GalNAc, giving rise to a structure
which is a better ligand for laminins and agrin [106]. The forced expres-
sion of B4galnt2 results in two main effects: i) inhibition of muscle
growth [107] and ii) increased expression of the extracellular matrix
proteins normally conﬁned to the synapse (laminins α4 and α5,
NCAM and utrophin) [99,101]. The ﬁrst effect is due to activation of
myostatin signaling [107], while the second is due to increased expres-
sion of the mRNA of genes encoding DAPC proteins, including agrin,
laminin α5, utrophin and integrin α7 [106].
Although the mechanism(s) linking B4galnt2 expression in skeletal
muscles and resistance to dystrophy are not completely elucidated, at
least part of this resistance is due to the Sda antigen on several DAPC
proteins, the most important of which is probably α-dystroglycan,
allowing their localization along the muscular ﬁbers, not only at the
neuromuscular junction. The presence of utrophin at sites in which
dystrophin is usually present allows utrophin to act as a dystrophin
“surrogate”. The ectopic extrasynaptic localization of utrophin in mus-
cular ﬁbers has also been observed in adult mice upon electrotransfer
of plasmid DNA carrying an expression cassette of B4galnt2 [108].
However, when B4galnt2 expression in muscular ﬁbers was mediated
after birth by transfer with an adeno-associated virus vector, muscles
develop normally, while the dystrophy is still prevented through an
utrophin-independent [109] mechanism. This ﬁnding suggests that
mechanisms other than that described above contribute to B4galnt2-
induced dystrophy prevention.
5.4. Phenotype of B4galnt2 knockout mice
The B4galnt2 KO mouse was generated by Core G of the Consortium
for Functional Glycomics (http://www.functionalglycomics.org). The pre-
liminary survey of its phenotype can be summarized as follows: there
are no obvious histological changes found in major organs and tissues.
In the blood, increased frequencies of Gr-1+ neutrophils and CD138+
(syndecan-1) plasma cells and a decrease of CD3+, CD62L+T-cells
were observed. In the bone marrow, there was a decrease of CD22+,
CD19+ B-cells. A double level of serum alkaline phosphatase was the
major serological alteration of KO mice. KO mice exhibited an increased
startled response (response to a sudden stimulus).A
Fig. 4. Simpliﬁed representation of dystrophin-associated protein complex (DAPC). A: DAPC
omitted for simplicity. The O-linked chains decorating α-dystroglycan (α-DG) in muscular ﬁ
neuromuscular junctions (B) these chains are terminated by β1,4-linked GalNAc (red circles), fo
β1,4-linked GalNAc is associated with ganglioside GM2 (green circles) and is recognized by ant6. Concluding remarks
Some crucial questions remain open despite long and intense
investigation in the ﬁeld.
First, through which mechanisms are the tissue- and stage-speciﬁc
expression of B4GALNT2 and the Sda antigen obtained? It is widely
accepted that B4GALNT2 is the only enzyme able to synthesize the Sda
antigen and that this enzyme is the product of a single genetic locus.
Thus, the most likely mechanism to achieve tissue-speciﬁc enzyme
expression is through the alternative use of different B4GALNT2 gene
promoters regulated by different sets of transcription factors. This
point is of special relevance to explain the fact that about half the people
with Sda− erythrocytes secrete Sda antigen in the urine [8,9]. This point
is also related to the very high level of enzyme expression achieved by
normal colonic mucosa and its dramatic down-regulation in cancer.
The removal of epigenetic marks, such as methylation of the B4GALNT2
promoter, in colon cancer cell lines does not appear to be sufﬁcient to
restore the high level of expression observed in normal colon, suggest-
ing a crucial role for transcription factors.
Second, what is the role of the enzyme's long isoform? Such a long
cytoplasmic tail is likely to be involved in very speciﬁc phenomena,
including a peculiar intracellular localization. Both the long and the
short protein isoforms are enzymatically active [53] and are able to
synthesize the Sda antigen in transfected cells. Owing to the fact that
the addition of β1,4-linked GalNAc must take place after the addition
of α2,3-linked sialic acid, the B4GALNT2 must be localized, at least in
part, in a Golgi compartment not preceding those containing α2,3-
sialyltransferases. However, other less conventional intracellular locali-
zations should be carefully considered.
Third, what is the role of the Sda antigen in pathogen resistance?
Bacterial adhesins may be speciﬁc for α2,3-sialylated glycoconjugates,
and a β1,4-linked GalNAc residue may hinder the attachment of
pathogenic bacteria expressing these adhesins. Consistent with this
hypothesis is the localization of the Sda antigen in tissues and organs,
such as colon and kidney, in close contact with the external
environment.
Some studies advocate the translational use of B4GALNT2 in disease
treatment. In particular, prevention of the metastatic phenotype of
colon cancer cells by down-regulation of sLex/a antigens will require
further validation in experimental systems before being considered for
therapeutic human use. Gene therapy protocols based on the overexpres-
sionof B4GALNT2 to treat patientswith various formsofmuscular dystro-
phy are currently under development and hopefully their efﬁcacy willB
of muscular ﬁbers; B: DAPC in neuromuscular junctions. Several DAPC components are
bers (A) are mainly O-mannosyl-linked α2,3-sialylated lactosaminic type chains. In the
rming the Sda antigens, which is recognized by CT2 antibody. In the presynaptic terminus,
ibody CT1.
451F. Dall'Olio et al. / Biochimica et Biophysica Acta 1840 (2014) 443–453soon be evaluated in clinical trials (http://www.nationwidechildrens.org/
muscular-dystrophy-podcast).
Sda antigen detection has frequently been based on the antibodies or
lectins summarized in Table 2. Although these tools remain invaluable
for most analyses, they do not provide information on the structures
carrying the antigen, which are often complex carbohydrate chains.
Furthermore, lectin-based detection of GalNAc residues is limited by
cross-reactivity with other α- or β-GalNAc residues. MALDI-TOF mass
spectrometry technology is the “state of the art” for complex carbohy-
drate analysis [110,111] and has recently been successfully used to elu-
cidate the structure of the N-linked chains of glycodelin [86,87] and the
O-linked carbohydrate chains of mucins in the adult and fetal human
gastrointestinal tract [64,112]. Future use of modern structural analysis
techniques will yield a more complete picture of the modulation of Sda
antigen expression in physiological and pathological conditions.Acknowledgement
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